Coya Therapeutics, Inc. (NASDAQ:COYA) Short Interest Up 5.6% in October

Coya Therapeutics, Inc. (NASDAQ:COYA) was the target of a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 196,500 shares, an increase of 5.6% from the October 15th total of 186,100 shares. Based on an average trading volume of 77,200 shares, the short-interest ratio is presently 2.5 days. Approximately 1.4% of the company’s shares are short sold.

Insider Activity

In other news, CEO Arun Swaminathan purchased 5,000 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The stock was acquired at an average cost of $7.34 per share, for a total transaction of $36,700.00. Following the completion of the purchase, the chief executive officer now owns 5,000 shares of the company’s stock, valued at approximately $36,700. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last 90 days, insiders have acquired 9,510 shares of company stock valued at $69,615. Company insiders own 9.80% of the company’s stock.

Institutional Trading of Coya Therapeutics

A number of hedge funds have recently modified their holdings of the company. Vanguard Group Inc. grew its stake in Coya Therapeutics by 772.3% in the first quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock valued at $8,407,000 after acquiring an additional 750,338 shares during the period. Geode Capital Management LLC boosted its stake in Coya Therapeutics by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock worth $918,000 after purchasing an additional 4,485 shares during the period. GHP Investment Advisors Inc. acquired a new stake in shares of Coya Therapeutics in the third quarter valued at approximately $169,000. Renaissance Technologies LLC bought a new position in Coya Therapeutics in the second quarter valued at $101,000. Finally, Gilbert & Cook Inc. bought a new stake in Coya Therapeutics during the 2nd quarter worth about $61,000. 39.75% of the stock is currently owned by institutional investors and hedge funds.

Coya Therapeutics Trading Up 0.2 %

Shares of COYA stock traded up $0.01 during trading hours on Tuesday, hitting $6.08. The company had a trading volume of 57,312 shares, compared to its average volume of 71,725. Coya Therapeutics has a 12 month low of $4.75 and a 12 month high of $10.69. The firm’s fifty day moving average is $7.12 and its 200 day moving average is $6.95.

Coya Therapeutics (NASDAQ:COYA) last issued its earnings results on Wednesday, November 6th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.15. Equities analysts anticipate that Coya Therapeutics will post -1.15 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Coya Therapeutics in a research report on Monday, November 11th. Chardan Capital reiterated a “buy” rating and issued a $14.00 target price on shares of Coya Therapeutics in a research report on Thursday, November 7th.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.